BRPI0408257A - uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map - Google Patents

uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map

Info

Publication number
BRPI0408257A
BRPI0408257A BRPI0408257-5A BRPI0408257A BRPI0408257A BR PI0408257 A BRPI0408257 A BR PI0408257A BR PI0408257 A BRPI0408257 A BR PI0408257A BR PI0408257 A BRPI0408257 A BR PI0408257A
Authority
BR
Brazil
Prior art keywords
related diseases
treat cancer
isoquinoline derivatives
kinase related
treatment
Prior art date
Application number
BRPI0408257-5A
Other languages
English (en)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lloyd Sabio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0408257A publication Critical patent/BRPI0408257A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE DERIVADOS DE ISOQUINOLINA PARA TRATAR CáNCER E DOENçAS RELACIONADAS COM QUINASE MAP". A presente invenção refere-se ao tratamento de uma doença que é caracterizada por uma via de sinalização da quinase MAP anormal através de administração de um composto da fórmula: em que os substituintes variáveis são aqui definidos, a um paciente que precisa de tal tratamento. O método da invenção é especialmente usado para o tratamento de cânceres que têm uma quinase RAF com mutação, especialmente melanoma.
BRPI0408257-5A 2003-03-11 2004-03-10 uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map BRPI0408257A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (1)

Publication Number Publication Date
BRPI0408257A true BRPI0408257A (pt) 2006-03-07

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408257-5A BRPI0408257A (pt) 2003-03-11 2004-03-10 uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map

Country Status (22)

Country Link
EP (1) EP1603566B1 (pt)
JP (1) JP2006519807A (pt)
KR (1) KR20050108383A (pt)
CN (1) CN1758910A (pt)
AT (1) ATE421324T1 (pt)
AU (1) AU2004218914A1 (pt)
BR (1) BRPI0408257A (pt)
CA (1) CA2518530A1 (pt)
DE (1) DE602004019193D1 (pt)
ES (1) ES2318276T3 (pt)
HR (1) HRP20050788A2 (pt)
IS (1) IS8064A (pt)
MA (1) MA27724A1 (pt)
MX (1) MXPA05009687A (pt)
NO (1) NO20054647L (pt)
PL (1) PL1603566T3 (pt)
PT (1) PT1603566E (pt)
RU (1) RU2325159C2 (pt)
TN (1) TNSN05223A1 (pt)
TW (1) TW200501955A (pt)
WO (1) WO2004080464A1 (pt)
ZA (1) ZA200506571B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006044869A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
HRP20110839T1 (hr) * 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CA2639416C (en) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
WO2020007807A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO2000009495A1 (en) * 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
NO20054647D0 (no) 2005-10-10
RU2005131168A (ru) 2006-05-27
CA2518530A1 (en) 2004-09-23
PT1603566E (pt) 2009-04-27
MA27724A1 (fr) 2006-01-02
NO20054647L (no) 2005-12-09
ES2318276T3 (es) 2009-05-01
CN1758910A (zh) 2006-04-12
KR20050108383A (ko) 2005-11-16
DE602004019193D1 (de) 2009-03-12
JP2006519807A (ja) 2006-08-31
EP1603566B1 (en) 2009-01-21
HRP20050788A2 (en) 2006-12-31
RU2325159C2 (ru) 2008-05-27
WO2004080464A1 (en) 2004-09-23
AU2004218914A1 (en) 2004-09-23
EP1603566A1 (en) 2005-12-14
MXPA05009687A (es) 2005-10-20
PL1603566T3 (pl) 2009-07-31
IS8064A (is) 2005-10-10
ZA200506571B (en) 2006-07-26
ATE421324T1 (de) 2009-02-15
TNSN05223A1 (en) 2007-06-11
TW200501955A (en) 2005-01-16

Similar Documents

Publication Publication Date Title
TNSN06093A1 (en) 1,4- disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
BRPI0408257A (pt) uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
CL2008003730A1 (es) Derivado de metastina ; profarmaco de dicho derivado; producto farmaceutico de dicho derivado; uso de dicho derivado para tratar metastasis de cancer o crecimiento del cancer.
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
ATE448232T1 (de) Substituierte heterozyklen
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
DE602004023271D1 (de) Metastin derivate und ihre verwendung
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
NO20050640L (no) Rutenium anticancer komplekser
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ATE386029T1 (de) Urokinase-inhibitoren
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
DE60120398D1 (de) Imidazopyridin-8-one

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.